Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle; F Peyraud; L Belcaid; M Brunet; M Aldea; R Clodion; P Dubos; D Vasseur; C Nicotra; A Geraud; M Sakkal; L Cerbone; F Blanc-Durand; F Mosele; P Martin Romano; M Ngo Camus; I Soubeyran; E Khalifa; M Alame; L Blouin; D Dinart; C Bellera; A Hollebecque; S Ponce; Y Loriot; B Besse; L Lacroix; E Rouleau; F Barlesi; F Andre; A Italiano

doi:10.1016/j.annonc.2022.08.089

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, D Vasseur, C Nicotra, A Geraud, M Sakkal, L Cerbone, F Blanc-Durand, F Mosele, P Martin Romano, M Ngo Camus, I Soubeyran, E Khalifa, M Alame, L BlouinD Dinart, C Bellera, A Hollebecque, S Ponce, Y Loriot, B Besse, L Lacroix, E Rouleau, F Barlesi, F Andre, A Italiano^*

^*Corresponding author for this work

Department of Oncology

51 Citations (Scopus)

Original language	English
Journal	Annals of Oncology
Volume	33
Issue number	12
Pages (from-to)	1328-1331
Number of pages	4
ISSN	0923-7534
DOIs	https://doi.org/10.1016/j.annonc.2022.08.089
Publication status	Published - Dec 2022

Keywords

Humans
Precision Medicine
Neoplasms/diagnosis
Liquid Biopsy

Access to Document

10.1016/j.annonc.2022.08.089

Cite this

Bayle, A., Peyraud, F., Belcaid, L., Brunet, M., Aldea, M., Clodion, R., Dubos, P., Vasseur, D., Nicotra, C., Geraud, A., Sakkal, M., Cerbone, L., Blanc-Durand, F., Mosele, F., Martin Romano, P., Ngo Camus, M., Soubeyran, I., Khalifa, E., Alame, M., ... Italiano, A. (2022). Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). Annals of Oncology, 33(12), 1328-1331. https://doi.org/10.1016/j.annonc.2022.08.089

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). / Bayle, A; Peyraud, F; Belcaid, L et al.
In: Annals of Oncology, Vol. 33, No. 12, 12.2022, p. 1328-1331.

Research output: Contribution to journal › Letter › peer-review

Bayle, A, Peyraud, F, Belcaid, L, Brunet, M, Aldea, M, Clodion, R, Dubos, P, Vasseur, D, Nicotra, C, Geraud, A, Sakkal, M, Cerbone, L, Blanc-Durand, F, Mosele, F, Martin Romano, P, Ngo Camus, M, Soubeyran, I, Khalifa, E, Alame, M, Blouin, L, Dinart, D, Bellera, C, Hollebecque, A, Ponce, S, Loriot, Y, Besse, B, Lacroix, L, Rouleau, E, Barlesi, F, Andre, F & Italiano, A 2022, 'Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)', Annals of Oncology, vol. 33, no. 12, pp. 1328-1331. https://doi.org/10.1016/j.annonc.2022.08.089

Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R et al. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). Annals of Oncology. 2022 Dec;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089

@article{33c31ae49a8a41cbac56f3d19fc60111,

title = "Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)",

keywords = "Humans, Precision Medicine, Neoplasms/diagnosis, Liquid Biopsy",

author = "A Bayle and F Peyraud and L Belcaid and M Brunet and M Aldea and R Clodion and P Dubos and D Vasseur and C Nicotra and A Geraud and M Sakkal and L Cerbone and F Blanc-Durand and F Mosele and \{Martin Romano\}, P and \{Ngo Camus\}, M and I Soubeyran and E Khalifa and M Alame and L Blouin and D Dinart and C Bellera and A Hollebecque and S Ponce and Y Loriot and B Besse and L Lacroix and E Rouleau and F Barlesi and F Andre and A Italiano",

year = "2022",

month = dec,

doi = "10.1016/j.annonc.2022.08.089",

language = "English",

volume = "33",

pages = "1328--1331",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer

T2 - a study from the French National Center for Precision Medicine (PRISM)

AU - Bayle, A

AU - Peyraud, F

AU - Belcaid, L

AU - Brunet, M

AU - Aldea, M

AU - Clodion, R

AU - Dubos, P

AU - Vasseur, D

AU - Nicotra, C

AU - Geraud, A

AU - Sakkal, M

AU - Cerbone, L

AU - Blanc-Durand, F

AU - Mosele, F

AU - Martin Romano, P

AU - Ngo Camus, M

AU - Soubeyran, I

AU - Khalifa, E

AU - Alame, M

AU - Blouin, L

AU - Dinart, D

AU - Bellera, C

AU - Hollebecque, A

AU - Ponce, S

AU - Loriot, Y

AU - Besse, B

AU - Lacroix, L

AU - Rouleau, E

AU - Barlesi, F

AU - Andre, F

AU - Italiano, A

PY - 2022/12

Y1 - 2022/12

KW - Humans

KW - Precision Medicine

KW - Neoplasms/diagnosis

KW - Liquid Biopsy

UR - https://www.scopus.com/pages/publications/85143144154

U2 - 10.1016/j.annonc.2022.08.089

DO - 10.1016/j.annonc.2022.08.089

M3 - Letter

C2 - 36122799

SN - 0923-7534

VL - 33

SP - 1328

EP - 1331

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

Keywords

Access to Document

Other files and links

Cite this